Demographic and Clinical Characteristics of RCC Patients in Libya:

a six year review

Authors

  • Ali Ben Omran MD, M.Sc, Alasmarya Islamic University, urology department, National Cancer Institute-Misrata, Zliten Medical Center, Libya. (ORCID ID: 0009-0005-1199-4279).
  • Refat Abusamra Associated professor.Misrata University. Head of urology department, National Cancer Institute-Misrata, Libya. (ORCID ID: 0009-0000-6555-0394).
  • Abubaker Abushnaf Assistant professor. Misrata University, urology department, National Cancer Institute-Misrata, Libya, (ORCID ID: 0000-0002-6648-5800).
  • Joma Alnari 4. M.D. urology department, National Cancer Institute-Misrata, Libya

DOI:

https://doi.org/10.59743/

Keywords:

clinical characters of RCC, RCC in libya, renal mass

Abstract

Worldwide, renal cell carcinoma (RCC) represents the sixth most frequently diagnosed cancer in men and the 10th in women, accounting for 5% and 3% of all oncological diagnoses, respectively. with the highest incidence occurring in Western countries. In 2020, Lithuania reported the highest overall rate of RCC, followed by Czechia. The incidence of renal cell carcinoma (RCC) has been increasing worldwide, largely due to the widespread use of new and improved, non-invasive abdominal imaging modalities, such as ultrasonography (US). Despite that, there is little information concerning the disease in Libya. The aim of this study is to describe the epidemiological profile, clinical characteristics, histopathological features, and type of surgery in patients diagnosed with RCC at National Cancer Institute NCI over a period of 6 years. According to this study in compared with the published data. some differences were noted. A higher number of patient were in younger age. O blood group was associated with a higher risk of RCC. Renal vein and IVC thrombus were seen in a higher percentage. Open surgeries still the standard surgical treatment for RCC at our center.

Downloads

Download data is not yet available.

References

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7–30.

.Capitanio, U., et al. Epidemiology of Renal Cell Carcinoma. Eur Urol, 2019. 75: 74.

.Bukavina, L., et al. Epidemiology of Renal Cell Carcinoma: 2022 Update. Eur Urol, 2022. 82: 529.

Hock LM, Lynch J, Balaji KC. Increasing incidence of allstages of kidney cancer in the last 2 decades in the UnitedStates: an analysis of Surveillance, Epidemiology and End Results Program data. J Urol. 2002;167:57– 60.

Lightfoot N, Conlon M, Kreiger N, et al. Impact of non inva-sive imaging on increased incidental detection of renal cellcarcinoma. Eur Urol. 2000;37:521–527.

Lucca I, Klatte T, Fajkovic H, De Martino M, Shariat SF. Gender differences in incidence and outcomes of urothelial and kidney cancer. Nat Rev Urol. 2015;12(10):585–92.

American Cancer Society. Cancer Facts & Figures 2024. Atlanta, Ga: American Cancer Society; 2024.

Lázaro M, Valderrama BP, Suárez C, et al. SEOM clinical guideline for treatment of kidney cancer (2019). Clin Transl Oncol 2020;22:256-69. 10.1007/s12094-019-02285-7

Heldwein FL, McCullough TC, Souto CA, et al. Localized renal cell carcinoma management: an update. Int Braz J Urol 2008;34:676-89; discussion 689-90.

Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003;27:612‑24.

Grignon DJ, Che M. Clear cell renal cell carcinoma. Clin Lab Med 2005;25:305‑16.

Bosniak MA. Observation of small incidentally detected re-nal masses. Semin Urol Oncol. 1995;13:267–272.

Bosniak MA, Birnbaum BA, Krinsky GA, Waisman J. Smallrenal parenchymal neoplasms: further observations ongrowth. Radiology. 1995;197:589 –597.

Bosniak MA, Krinsky GA, Waisman J. Management of smallincidental renal parenchymal tumors by watchful-waiting inselected patients based on observations of tumor growthrates [abstract]. J Urol. 1996;155(Suppl):584A.

.Scelo G., Li P., Chanudet E., Muller D.C. Variability of Sex Disparities in Cancer Incidence over 30 Years: The Striking Case of Kidney Cancer. Eur. Urol. Focus. 2018;4:586–590.

Thomas MC, Walker RJ, Kankatsu Y. cc. Nephrol Dial Transplant. 1998; 13: 1811–1814.

Lugo A, Bosetti C, Peveri G, et al. Dose–response relationship between cigarette smoking and site-specific cancer risk: protocol for a systematic review with an original design combining umbrella and traditional reviews. BMJ Open 2017;7:e018930.

.Michela de Martino, Matthias Waldert, Andrea Haitel, et al. Evaluation of ABO blood group as a prognostic marker in renal cell carcinoma (RCC). BJU Int. 2013;

Delahunt B, Bethwaite P, Nacey JN. Renal cell carcinoma in New Zealand: a national survival study. Urology. 1994;43(3):300-309.

Campbell SC, Lane BR. Campbell-Walsh Urol. 2012. Malignant renal tumors.

.Moinzadeh et al. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same? J Urol 2004;171:598-601.

Agnihotri S, Kumar J, Jain M, Kapoor R, Mandhani A. Renal cell carcinoma in India demonstrates early age of onset and a late stage of presentation. Indian J Med Res. 2014;140:624–9.

Khafaja S, Kourie HR, Matar D, Ghorra CS, Kattan J. Kidney Cancer in Lebanon: a Specific Histological Distribution? Asian Pac J Cancer Prev. 2015;16(1):363–5.

Downloads

Published

03-10-2025

Issue

Section

Applied Sciences

Categories

How to Cite

Ben Omran, A. ., Abusamra, R. ., Abushnaf, A. ., & Alnari, . J. . (2025). Demographic and Clinical Characteristics of RCC Patients in Libya:: a six year review. Journal of the Academic Forum, 9(2), 291-303. https://doi.org/10.59743/